Among 220 B-ALL patients, the presence of CDKNA/2B deletions was identified in 49/220 (22.3%), and within the 27 T-ALL subsets, CDKN2A/2B deletions were present in 14/27 patients (51.8%). Here, CDKN2A is linked to acute lymphoblastic leukemia.